In clinical development, speed isn’t just a competitive advantage, it’s a lifeline. Yet most trials are still governed by outdated systems, fragmented data, and manual processes that drive up costs and delay decisions. In an era defined by precision medicine, real-time insights, and rising complexity, the way we run trials is overdue for reinvention.
At OmniScience, we’ve spent the last several years building Vivo, the first agentic AI system designed specifically for clinical trial oversight. Not just another dashboard or analytics engine, Vivo acts like a strategic partner embedded inside your operations - anticipating delays, detecting risks, and recommending next-best actions in real time.
And the impact? It’s not theoretical.
Vivo delivers:
In our new whitepaper, Transforming Trial Economics, we walk through exactly how this is achieved - breaking down real-world efficiencies across enrollment, vendor oversight, safety signal detection, and trial reconciliation.
Manual processes are costing sponsors millions.
The average Phase 2 trial takes 3.5 years and costs $20M - much of this budget is consumed by redundant workflows and preventable delays. By embedding agentic AI directly into trial infrastructure, Vivo unlocks significant time and cost savings while empowering study teams to operate with real-time clarity and control.
This is more than an efficiency play.
Vivo gives sponsors strategic flexibility: test more candidates, explore more indications, or reinvest savings into high-impact trials. Across entire portfolios, these gains compound turning trial operations into a powerful lever for innovation and growth.
If you could unlock 20% of your trial budget, how would you use it?
Would you reduce operational costs? Accelerate timelines? Expand your pipeline?
We believe the future of clinical development will be built by teams who don’t just manage trial data - but activate it.
